BiondVax Announces Pricing of Public Offering of American Depositary Shares

NESS ZIONA, Israel, Sept. 13, 2017 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV, TASE: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate, announced today that it has priced an underwritten public offering of 1,500,000 American Depositary Shares ("ADS"), each ADS representing forty (40) of its ordinary shares which are listed on the Tel Aviv Stock Exchange (at NIS 0.0000001 par value each), at a price to the public of $6.00 per ADS.

BiondVax Pharmaceuticals has granted the underwriter a 45-day option to purchase up to 166,667 additional ADS. The offering is expected to close on or about September 18, 2017, subject to satisfaction of customary closing conditions.

Dr. Ron Babecoff, BiondVax's CEO, commented, "This financing, together with the €20 million EIB funding, the Israeli Government support, and our other existing resources enables us to launch our Phase 3 program including a mid-size manufacturing facility."

Joseph Gunnar & Co., LLC is acting as the sole book-running manager for the offering.

The ADSs described above will be issued pursuant to a registration statement on Form F-3 previously filed with and subsequently declared effective by the Securities and Exchange Commission (SEC) on December 15, 2016. The securities may be offered only by means of a prospectus and related prospectus supplement. A preliminary prospectus supplement and accompanying prospectus relating to the offering has been filed with the SEC and will be available on the SEC's website at http://www.sec.gov.

Before buying any of BiondVax's ADSs in the offering, investors should carefully read the preliminary prospectus supplement and the accompanying prospectus, together with the information incorporated by reference therein. These documents contain important information that investors should consider when making their investment decisions. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to these ADSs may be obtained by contacting Joseph Gunnar & Co., LLC, Prospectus Department, 30 Broad Street, 11th Floor, New York, NY 10004, telephone 212-440-9600, email: prospectus@jgunnar.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About BiondVax
BiondVax is a biopharmaceutical company developing M-001, a universal flu vaccine candidate approaching Phase 3 clinical trials. The vaccine is designed to provide multi-season protection against most seasonal and pandemic human influenza virus strains. BiondVax's proprietary technology utilizes a unique combination of conserved and common peptides from influenza virus proteins, activating both arms of the immune system for a cross-protecting and long-lasting effect. BiondVax is traded on NASDAQ: BVXV and TASE: BVXV. For more information, please visit www.biondvax.com.

Contact Details
Joshua Phillipson
Business Development
+972-8-930-2529
j.phillipson@biondvax.com  

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve certain risks and uncertainties reflect the management's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of BiondVax Pharmaceuticals Ltd. risks and uncertainties include, but are not limited to, the risk that drug development involves a lengthy and expensive process with uncertain outcome, the results of the contemplated  Phase 2 & 3 trials, delays or obstacles in launching and/or successfully completing our clinical trials, the impact of the global economic environment on the Company customer target base, the adequacy of available cash resource and the ability to raise capital when needed. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2016 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC's website, www.sec.gov, and in the Company's periodic filings with the SEC and the Tel-Aviv Stock Exchange.

View original content:http://www.prnewswire.com/news-releases/biondvax-announces-pricing-of-public-offering-of-american-depositary-shares-300519353.html

SOURCE BiondVax Pharmaceuticals Ltd.